Acadia Pharmaceuticals (NASDAQ:ACAD) announced today that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a new dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in both adult and pediatric patients aged two years and older.
Relay Therapeutics (NASDAQ:RLAY) presented promising subset efficacy data from its ReDiscover program at the 2025 San Antonio Breast Cancer Symposium (SABCS), showcasing the combination of zovegalisib (RLY-2608) and fulvestrant in a cohort of 52 patients with estrogen receptor-positive breast cancer.
BeyondSpring (NASDAQ:BYSI) presented encouraging results from the Asian subset of its global Phase 3 DUBLIN-3 trial at ESMO Asia 2025, evaluating the combination of plinabulin and docetaxel versus docetaxel alone in second-line and third-line EGFR wild-type non-small cell lung cancer (NSCLC).
OKYO Pharma (NASDAQ:OKYO) announced on December 11, 2025, new analyses from its Phase 2, placebo-controlled, randomized, double-masked trial of 0.05% urcosimod for the treatment of neuropathic corneal pain (NCP).
The trial, involving 18 patients, provided exploratory data on corneal nerve imaging using in vivo confocal microscopy.
